source
- Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programsVir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer. Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZene…
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trialCerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the ca…